About US
Contact us
-
FDA flags cataract risk in kids using Vertex's KalydecoVertex Pharmaceuticals ($VRTX) has hit an unexpected snag with itscystic fibrosispillKalydeco. The FDA is raising questions about a potential risk of cataracts in children using the drug, and asked th2012/8/31
-
New method simplifies pharmaceutical production of proteinsEngineering researchers at the University of Arkansas have developed a method to simplify the pharmaceutical production of proteins used in drugs that treat a variety of diseases and health conditions2012/8/30
-
Voters need more information on free trade agreement that could impact drug pricesIn anopinion piecein the Guardian's "Comment is Free" blog, Dean Baker, co-director of the Center for Economic and Policy Research, discusses potential policies contained within the "Trans-Pacific Par2012/8/30
-
AstraZeneca entices Roche exec to take on CEO challengeAstraZeneca ($AZN) turned heads today with an unexpectedly intriguing CEO choice: Roche's ($RHHBY) Pascal Soriot, who's been the Swiss drugmaker's COO and pharma chief since 2010. Within hours, Sori2012/8/29
-
Sanofi recalls 9 lots of Genzyme transplant drugGenzyme is pulling 9 lots of its kidney transplant drug Thymoglobulin after one lot failed a stability test. The company, which is Sanofi's ($SNY) U.S.-based rare disease division, pulled all lots2012/8/29
-
Lilly's Effient hopes dashed by head-to-head Plavix trialIt's another R&D stumble for Eli Lilly ($LLY). The clotbusting drug Effient, one of its newer products, failed to come through in a head-to-head study against Plavix. The trial, which tested the t2012/8/28
-
Take a gander at Glaxo's up-and-coming Philly buildingGlaxoSmithKline ($GSK) got a lot of local kudos when it inked a deal to relocate its Philadelphia offices to a brand-spanking-new building at the Navy Yard. City officials have been trying to develo2012/8/28
-
New Roche breast cancer drug delivers overall survival resultsRoche's ($RHHBY) experimental breast cancer drug T-DM1 hit another study target, prompting analysts to predict regulatory approval during the first half of next year. After showing it can hold off tum2012/8/28
-
GSK's wind turbine plan blows, Scots suggestGlaxoSmithKline's ($GSK) effort to go green at one of its Scottish plants by using wind turbines is facing some ill winds. In the coastal town of Montrose, townspeople want to put the kibosh on GSK's2012/8/27
-
Pfizer severs supply deal with India's ClarisEven as other companies are tightening links with Indian generics makers, Pfizer has killed another marriage, this one with Claris Lifesciences. Pfizer called off a proposed marketing agreement with2012/8/27